VolitionRx Ltd. (NYSE American: VNRX) announced a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc. (NASDAQ: HOLX), to promote Volition's Nu.Q® Discover service. This program provides drug developers and scientists with assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, stated, "This is a significant milestone for our Nu.Q® Discover program and will greatly expand customer access to our proprietary Nu.Q® Discover assays, which have an estimated total addressable market of $200 million annually." She added, "We look forward to working with the Hologic team as we strengthen our position in the pharmaco-epigenetics market, to help us to grow our revenues."
Raphael Werding, Head of Life Sciences at Hologic, commented, "We are delighted to sign this agreement and add Nu.Q® Discover to our service offering. At Hologic, we have extensive experience not only in oncology but also in other disease areas such as cardiovascular, neurodegenerative, immunology and others; disease areas where we believe nucleosome quantification can provide additional valuable biological insights to our biotech, pharma and academic clients."
Under the agreement, Hologic will co-market Nu.Q® Discover with its customer base for an initial one-year term, with the potential to expand into an exclusive provider arrangement subject to further terms. The partnership leverages Hologic's established presence in life sciences to broaden access to Volition's epigenetic profiling tools.
Volition is a multinational epigenetics company focused on developing blood tests for early detection and monitoring of diseases, including certain cancers and sepsis. The Nu.Q® Discover service aims to accelerate drug development by enabling rapid epigenetic analysis, a field with growing importance in precision medicine. The agreement marks a strategic step for Volition to commercialize its technology through a major diagnostics partner, potentially increasing adoption among biotech and pharmaceutical researchers.
For more details, the full press release is available at https://ibn.fm/Spd1c. Information about Volition can be found at www.Volition.com.
